ACADIA Pharmaceuticals Inc. (ACAD)
Automate Your Wheel Strategy on ACAD
With Tiblio's Option Bot, you can configure your own wheel strategy including ACAD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ACAD
- Rev/Share 6.202
- Book/Share 5.4329
- PB 4.8096
- Debt/Equity 0.0598
- CurrentRatio 3.0187
- ROIC 0.2332
- MktCap 4420720878.0
- FreeCF/Share 1.1716
- PFCF 22.3483
- PE 16.8917
- Debt/Assets 0.0412
- DivYield 0
- ROE 0.3227
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ACAD | Citigroup | -- | Buy | -- | $33 | Oct. 21, 2025 |
| Upgrade | ACAD | Deutsche Bank | Hold | Buy | -- | $35 | May 21, 2025 |
| Initiation | ACAD | Deutsche Bank | -- | Hold | -- | $22 | Feb. 11, 2025 |
| Downgrade | ACAD | Guggenheim | Buy | Neutral | $23 | $20 | Jan. 3, 2025 |
| Resumed | ACAD | Raymond James | -- | Market Perform | -- | -- | Oct. 10, 2024 |
News
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.
Read More
Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Positive
Class A shares of the Alger Weatherbie Specialized Growth Fund outperformed the Russell 2500 Growth Index during the fourth quarter of 2025. Natera, Inc., ACADIA Pharmaceuticals Inc., and Glaukos Corp were among the top contributors to performance. FirstService Corp, AAR CORP., and Kratos Defense & Security Solutions, Inc. were among the top detractors from performance.
Read More
Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Negative
ACAD expects a negative CHMP opinion on trofinetide marketing application for Rett syndrome, likely delaying a potential EU approval.
Read More
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
Published: February 02, 2026 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company was informed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of a negative trend vote on its Marketing Authorization Application (MAA) for trofinetide for the treatment of Rett syndrome, following its recent CHMP oral explanation. Subject to the outcome of the CHMP vote in February, Acadia intends to request a re-examination of the opinion b.
Read More
Why Acadia (ACAD) is Poised to Beat Earnings Estimates Again
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Positive
Acadia (ACAD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
FTRE or ACAD: Which Is the Better Value Stock Right Now?
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?
Read More
FTRE vs. ACAD: Which Stock Is the Better Value Option?
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Fortrea Holdings Inc. (FTRE) or Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Is Acadia (ACAD) Up 22.6% Since Last Earnings Report?
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Read More
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Neutral
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Read More
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Acadia's third-quarter earnings and revenues top forecasts as Nuplazid and Daybue sales power double-digit annual growth.
Read More
Acadia (ACAD) Moves to Buy: Rationale Behind the Upgrade
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Acadia (ACAD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Does Acadia (ACAD) Have the Potential to Rally 27.66% as Wall Street Analysts Expect?
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Acadia (ACAD) points to a 27.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights
Published: October 22, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) breached their fiduciary duties to shareholders. If you currently own Acadia stock and acquired shares on or before September 9, 2019, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here t.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Published: October 13, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
QGEN vs. ACAD: Which Stock Is the Better Value Option?
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen (QGEN) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Negative
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
Read More
Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
Read More
GMAB vs. ACAD: Which Stock Is the Better Value Option?
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Acadia Pharmaceuticals (ACAD). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
KMDA or ACAD: Which Is the Better Value Stock Right Now?
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Acadia Pharmaceuticals (ACAD). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
KMDA vs. ACAD: Which Stock Is the Better Value Option?
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Kamada (KMDA) or Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?
Read More
Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Read More
Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025
Published: June 05, 2025 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will host a R&D day in New York City to discuss its neurological and rare diseases pipeline on Wednesday, June 25, 2025 at 8:30 AM ET. The event will feature members of Acadia's management team and R&D organization, key opinion leaders (KOL) and members of the caregiver community. To register for the live webcast, please click here. A replay of Acadia's R&D Day will be available on the company'.
Read More
GSK or ACAD: Which Is the Better Value Stock Right Now?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of GSK (GSK) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?
Read More
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
Read More
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation
Published: May 16, 2025 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware ruled in favor of Acadia regarding its ‘721 formulation patent for NUPLAZID® (pimavanserin), Acadia's drug for the treatment of Parkinson's Disease Psychosis. In today's order, the Court ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated.
Read More
About ACADIA Pharmaceuticals Inc. (ACAD)
- IPO Date 2004-05-27
- Website https://www.acadia-pharm.com
- Industry Biotechnology
- CEO Catherine E. Owen Adams
- Employees 653